However, some patients either do not respond to MEK inhibitor monotherapy, including selumetinib, binimetinib, and trametinib [18,19,20], or eventually develop MPNST within a few months of treatment, indicating that MEK inhibitor monotherapy may be insufficient to prevent malignant transformation [21]. This evidence concerns the gene MAP2K7 and malignant peripheral nerve sheath tumor.